Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

6.42
+1.9242.67%
Post-market: 6.39-0.0300-0.47%19:59 EDT
Volume:31.68M
Turnover:189.32M
Market Cap:297.40M
PE:-2.02
High:6.69
Open:5.28
Low:4.99
Close:4.50
Loading ...

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

GlobeNewswire
·
01 May

Discover Fractyl Health And 2 More Promising Penny Stocks

Simply Wall St.
·
22 Apr

4DMT Announces New Employment Inducement Grants

GlobeNewswire
·
12 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

4DMT to Participate in Upcoming Investor Conferences

GlobeNewswire
·
27 Mar

4D Molecular Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
11 Mar

BRIEF-4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy

Reuters
·
10 Mar

Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), 4D Molecular Therapeutics (FDMT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
05 Mar

4D Molecular price target lowered to $35 from $39 at RBC Capital

TipRanks
·
04 Mar

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating

MT Newswires Live
·
04 Mar

4D Molecular price target lowered to $28 from $30 at Chardan

TIPRANKS
·
04 Mar

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
04 Mar

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
03 Mar

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Mar

Promising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating

TIPRANKS
·
03 Mar

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alcon (ALC) and Cooper Co (COO)

TIPRANKS
·
03 Mar

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
02 Mar

4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position

TIPRANKS
·
02 Mar

4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
01 Mar